Daiichi Sankyo Co., Ltd.: A Modern Company Built on Old World Traditions

DAIICHI SANKYO COMPANY LIMITED was established on September 28, 2005 as the joint holding company of two major Japanese pharmaceutical companies - Sankyo Co., Ltd. and Daiichi Pharmaceutical Co., Ltd.  DAIICHI SANKYO aims to become a Global Pharma Innovator, continuously generating innovative drugs and services and maximizing its corporate value.

Sankyo and Daiichi Pharmacuetical have a broad range of major drug products on the Japanese market, including the antihypertensive Olmetec® (olmesartan medoxomil) and the synthetic antibacterial agent Cravit® (levofloxacin) and are strongly promoting drug information provision activities.  Both companies specialize in the field of cardiovascular disease and have used their cumulative knowledge and expertise as a foundation for developing an abundant product lineup and R&D pipeline.

DAIICHI SANKYO CO., LTD. and Luitpold Pharmaceuticals, Inc., a wholly owned subsidiary of Daiichi Sankyo, remain committed to improving the health and lives of people everywhere.

For further details, please refer to the company website at www.daiichisankyo.co.jp/eng